Dexcel Pharma Technologies Ltd. - 22 Apr 2022 Form 4 Insider Report for Roivant Sciences Ltd. (ROIV)

Reporting relationship: 10%+ Owner
Issuer ticker: ROIV
Reported as of: 22 Apr 2022
Net transaction value: +$154,954
SEC form: 4
Accepted by SEC: 26 Apr 2022, 06:48:12 UTC
Prior SEC filing: 01 Oct 2021
Next SEC filing: 14 Nov 2022
Source filing: View source filing
Reporting owner signature: /s/ Dexcel Pharma Technologies Ltd. by Dan Oren, Executive Chairman

Key filing fact

Dexcel Pharma Technologies Ltd. filed Form 4 for Roivant Sciences Ltd. (ROIV) on 26 Apr 2022.

Key facts

This page summarizes Dexcel Pharma Technologies Ltd.'s Form 4 filing for Roivant Sciences Ltd. (ROIV).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 26 Apr 2022, 06:48.

Change

Previous filing in this sequence was filed on 01 Oct 2021.
Current net transaction value: +$154,954.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ROIV transaction

Common Shares

Purchase

Transaction value: $121,319
Shares: +31,685
Change %: +0.03%
Price: $3.83
Shares after: 98,840,843
Date: 22 Apr 2022
Ownership: Direct
Footnotes: F1, F2, F4

ROIV transaction

Common Shares

Purchase

Transaction value: $33,635
Shares: +8,600
Change %: +0.01%
Price: $3.91
Shares after: 98,849,443
Date: 25 Apr 2022
Ownership: Direct
Footnotes: F1, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Dexcel Pharma Technologies Ltd. ("Dexcel") is the direct beneficial holder of 684,130 common shares. Dexxon Holding Ltd. ("Dexxon") is the direct beneficial holder of 98,165,313 common shares. Dan Oren is the Executive Chairman of Dexcel and the sole director of Dexxon and is ultimately the sole shareholder of each entity.

Footnote F2

The price reported in Column 4 is the weighted average price. The common shares were purchased in multiple transactions at prices ranging from $3.685 to $3.88.

Footnote F3

The price reported in Column 4 is the weighted average price. The common shares were purchased in multiple transactions at prices ranging from $3.825 to $3.99.

Footnote F4

The Reporting Persons hereby undertake to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.